Gismo Therapeutics Inc. is a preclinical-stage biopharmaceutical company targeting fundamental biochemical processes that are at the root cause of neurodegenerative diseases. The company has been awarded several prestigious grants to develop its industry-leading technology. Gismo Therapeutics Inc. is developing first-in-class, disease modifying therapeutics for Alzheimer’s and Parkinson's Disease. GTC-3295, the lead products in preclinical development, has shown robust data and proof of principle in animal studies together with a very good safety profile. The company was incorporated in Delaware and has offices in Lexington, Kentucky and Queens, New York. The company was founded by Paul Gregor, Ph.D., CEO, a graduate of the Weizmann Institute of Science (Rehovot, Israel). Its Scientific Advisory Board includes Dennis Choi, M.D., Ph.D., an award-winning neurologist, Chair of Department of Neurology and Director of the Neuroscience Institute, Stony Brook University, New York.
Gismo Therapeutics Inc. is presenting as part of the NIH Innovation Zone.